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ABSTRACT
Transthyretin (TTR) transports the
retinol-binding protein–vitamin A complex
and is a minor transporter of thyroxine in
blood. Its tetrameric structure undergoes
rate-limiting dissociation and monomer
misfolding, enabling TTR to aggregate or to
become amyloidogenic. Mutations in the TTR
gene generally destabilize the tetramer and/or
accelerate tetramer dissociation, promoting
amyloidogenesis. TTR-related amyloidoses are
rare, fatal, protein-misfolding disorders,
characterized by formation of soluble
aggregates of variable structure and tissue
deposition of amyloid. The TTR amyloidoses
present with a spectrum of manifestations,
encompassing progressive neuropathy and/or
cardiomyopathy. Until recently, the only
accepted treatment to halt progression of
hereditary TTR amyloidosis was liver
transplantation, which replaces the hepatic
source of mutant TTR with the less
amyloidogenic wild-type TTR. Tafamidis
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meglumine is a rationally designed, non-NSAID
benzoxazole derivative that binds with high
affinity and selectivity to TTR and kinetically
stabilizes the tetramer, slowing monomer
formation, misfolding, and amyloidogenesis.
Tafamidis is the first pharmacotherapy
approved to slow the progression of peripheral
neurologic impairment in TTR familial amyloid
polyneuropathy. Here we describe the
mechanism of action of tafamidis and review
the clinical data, demonstrating that tafamidis
treatment slows neurologic deterioration and
preserves nutritional status, as well as quality of
life in patients with early-stage Val30Met
amyloidosis.
Keywords: Familial amyloid cardiomyopathy;
Familial amyloid polyneuropathy; Hereditary
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INTRODUCTION
The transthyretin (TTR)-related amyloidoses are
rare, fatal protein misfolding and aggregation
disorders. Historically, the TTR amyloidoses
were grouped into three categories: (1)
wild-type TTR amyloidosis (TTRwt), formerly
known as senile systemic amyloidosis,
presenting as a cardiomyopathy and involving
the aggregation of wild-type (WT) TTR; (2)
familial amyloid polyneuropathy (FAP); and
(3) hereditary TTR amyloid cardiomyopathy,
formerly known as familial amyloid
cardiomyopathy (FAC). Both hereditary forms
involve aggregation of primarily mutant TTR.
Current knowledge suggests that the TTR
amyloidoses do not fit neatly into these
categories, as patients often exhibit a spectrum
of phenotypes depending on mutation, genetic
background, and extent of progression.
Non-fibrillar aggregates and amyloid composed
of mutant and/or WT TTR of hepatic origin
accumulate in various tissues and organs,
particularly the peripheral and autonomic
nerves and heart, leading to tissue damage and
end-organ failure [1–3]. TTR gene expression by
the choroid plexus and retinal pigmented
epithelium leads to leptomeningeal and ocular
degeneration linked to TTR amyloidogenesis,
respectively [4].
Tafamidis (2-(3,5-dichloro-phenyl)-benzoxazole-
6-carboxylic acid) is a once-daily, orally
bioavailable, non-NSAID small molecule, and
specific kinetic stabilizer of TTR [5]. In clinical
studies, tafamidis slowed peripheral neurologic
impairment and additional clinical
manifestations in patients with Val30Met
amyloidosis and was associated with an
excellent safety profile [6–8]. Tafamidis is the
first pharmacotherapy approved to treat
TTR-FAP in the European Union and several
countries in Latin America and the Asia-Pacific
including Argentina and Japan.
The aim of this article is to focus on TTR as a
drug target, to provide the rationale used in the
development of tafamidis, and review
comprehensively the pharmacology of this
disease-modifying therapy for TTR
amyloidoses. This article is based on
previously conducted studies and does not
involve any new studies of human or animal
subjects performed by any of the authors.
STRUCTURE AND FUNCTIONS
OF TTR
Transthyretin, also known as prealbumin, is a
soluble, b-sheet rich, 127-amino acid,
non-glycosylated protein primarily synthesized
and secreted into the blood by the liver. TTR
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circulates in the blood predominantly as a
55 kDa tetramer, along with a very small
amount of dissociated monomer [6].
The monomeric subunits of TTR fold into a
b-sandwich tertiary structure that
spontaneously assembles into a tetramer
within the cellular endoplasmic reticulum. The
tetramer exhibits two distinct dimer–dimer
interfaces, the less stable of which makes up
two highly conserved thyroxine (T4) binding
sites [9–13]. The three-dimensional structures of
the TTR tetramer bound to T4 and its other
known ligand, the vitamin A–retinol-binding
protein complex, have been solved [14–16].
Transthyretin is expressed from embryonic
development through adult life and its blood
concentration over this time reflects those of
total body nitrogen and total body potassium
levels [17]. Serum TTR concentration so closely
mimics the body’s nitrogen balance that it has
been widely used as a marker of malnutrition
and inflammation in several conditions [17–19].
In fact, TTR is a negative acute phase reactant
[20]. In adult humans, plasma TTR
concentrations range from 3 to 6 lM; the TTR
concentration in cerebrospinal fluid is an order
of magnitude lower (approximately 0.36 lM)
[21–23]. The half-life of TTR in vivo blood is
24–48 h [22, 24, 25].
In blood, the TTR tetramer binds
retinol-binding protein bound to retinol
(holo-retinol-binding protein) and a small
amount of T4, and transports them to tissues on
the minute-to-hour timescale [9, 26, 27].
Although TTR is the only known transporter of
circulating holo-retinol-binding protein that
facilitates retinol transport, two other proteins,
namely, albumin and thyroid binding globulin
transport thyroid hormones. Of the three T4
binding proteins, albumin has by far the highest
plasma concentration and thyroid binding
globulin has the highest affinity for T4 [28, 29].
Thus, given the low level of circulating T4, less
than 10% of T4 in blood is bound to TTR and more
than 99% of the T4 binding sites in circulating
TTR are vacant [21]. Thus, TTR is thought to play
only a minor role in the physiological transport of
T4. In contrast, TTR is the primary T4 carrier in
cerebrospinal fluid [10].
In addition, transthyretin may be a natural
detoxifier, as its T4 binding sites bind small
molecules with substituted aromatic rings
connected by linkers of variable chemical
composition [30]. These structures include
stilbenes, flavones, benzoxazoles,
tetrahydroquinolines, dihydropyridines,
benzodiazepines, and phenoxazines [31, 32].
Emerging evidence suggests that WT TTR may
also have a protective effect in Alzheimer’s
disease through an interaction with the
amyloidogenic Ab-amyloid peptide [30]. TTR
has also been shown to influence nerve
physiology and to enhance nerve regeneration
in the mouse [33]. A role for TTR in nerve
biology and repair may explain the preferential
deposition of mutant TTR aggregates in the
peripheral nervous system of patients with
TTR-FAP [33].
MOLECULAR MECHANISM OF TTR
AMYLOIDOGENESIS
Experiments with cell lines and Drosophila
melanogaster model systems demonstrate the
proteotoxicity associated with various TTR
sequences linked to pathology [3, 34–39].
Biophysical in vitro studies suggest that
tetrameric TTR protein does not form amyloid
fibrils and that amyloidogenesis starts with TTR
tetramer dissociation into dimers, which then
rapidly dissociate to folded monomers (Fig. 1a)
[23, 40–45]. Amyloid fibrillogenesis appears to
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require partial denaturation of released
monomers, which exposes stretches of
hydrophobic residues that misassemble into
spherical aggregates which then undergo
conformational conversion into cross-b sheet
assemblies [46–49]. In vitro, amyloid formation
by TTR monomers proceeds in an energetically
downhill polymerization process that is fast
compared with the initial tetramer dissociation
[50]. Thus, tetramer dissociation is thought to
be rate limiting for TTR amyloid formation in
the case of the WT protein and most tetramers
produced by heterozygotes comprising mutant
and WT TTR subunits [45].
Most amyloidogenic TTR variants form
approximately 6% homotetramers and
approximately 87% variant/WT
heterotetramers with reduced kinetic or
thermodynamic stabilities relative to WT
homotetramers (approximately 6%), which
renders them more prone to tetramer
dissociation and amyloid formation [43, 45].
Oxidative modifications have also been found
to energetically destabilize the tetrameric
structure and to increase the amyloidogenic
potential of TTR protein in vitro [51, 52]. Given
the well-established increase in protein
oxidation with ageing, this may contribute to
senile forms of TTR amyloidosis [52].
Increasing evidence indicates that
proteolytic cleavage may also play a role in
TTR amyloid formation. Analyses of ex vivo TTR
amyloid fibrils have revealed that, in addition to
full-length protein, amyloid deposits in patients
with TTRwt amyloidosis contain a high
proportion of C-terminal TTR fragments
starting at amino acid residues 46, 49, 52, or
53 [53–55]. Similarly, in patients with
hereditary TTR amyloidosis, amyloid fibrils
with N-terminally truncated TTR were
observed more frequently than amyloid fibrils
containing predominantly full-length TTR
protein [55–57]. Based on the small N-terminal
cleavage products detected at very low amounts
in amyloid fibrils, it has been speculated that
proteolytic cleavage may occur prior to and play
a role in fibrillogenesis [53, 54]. A recent study
suggests that, at least for the Ser52Pro
(p.Ser72Pro) variant, proteolytic cleavage of
the Lys48–Thr49 peptide bond may indeed be
a prefibrillar event in vivo which produces a
C-terminal fragment that, once released from
the TTR tetramer, is highly fibrillogenic at
physiological pH in vitro [58].
CLINICAL OVERVIEW OF TTR
AMYLOIDOSES
The hereditary TTR amyloidoses are rare,
autosomal dominant diseases caused by point
mutations in the TTR gene [27, 59–62]. More
than 100 destabilizing mutations of TTR have
been identified [63]. The propensity for a
particular TTR mutant to undergo
amyloidogenesis in vitro depends on the
thermodynamic and kinetic destabilization of
the tetramer caused by the substitution [23, 27,
42–45]. However, the most amyloidogenic TTR
mutants (e.g., Asp18Gly [p.Asp38Gly] and
Ala25Thr [p.Ala45Thr]) do not cause the most
severe, early-onset systemic amyloid disease
because they are degraded by the quality
control system located in the endoplasmic
reticulum of liver cells [27, 45]. Thus, for these
two mutants, the concentration of destabilized
mutant TTR in blood is insufficient to result in
systemic amyloidogenesis; however, late-onset
central nervous system (CNS) pathology is
observed [64, 65].
Although the main pathologic manifestation
of hereditary TTR amyloidosis is a progressive
ascending polyneuropathy and/or
cardiomyopathy, mixed phenotypes, extreme
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phenotypic variability, and incomplete
penetrance often obscure a proper diagnosis
for physicians not considering TTR amyloidosis
[62, 66–69]. As a consequence, hereditary TTR
amyloidosis is under-recognized and often
misdiagnosed.
Most known cases of TTR-FAP result from the
Val30Met (p.Val50Met) mutation, which is
particularly frequent in regions of Portugal,
Japan, Sweden, and Brazil [68, 70].
Importantly, age at onset of symptoms and
disease penetrance of the Val30Met mutation is
very heterogeneous [70–72]. TTR-FAP is
characterized by a length-dependent sensory,
motor, and autonomic neuropathy [68].
Gastrointestinal symptoms are a common
complication of autonomic neuropathy.
Amyloid deposits, typically found in ganglia,
the endoneurium, and nerve blood vessels, lead
to the reduction of nerve fiber density and
eventual destruction of unmyelinated nerve
fibers, and then small and large myelinated
nerve fibers [68, 73]. Distal axonal degeneration
is the main pathogenic feature. Possible
underlying mechanisms that are not mutually
exclusive include: (1) a combination of toxic
and mechanical effects of fibrillar amyloid
deposits on nerve fibers [68, 74]; and/or (2)
the proteotoxicity of non-amyloid TTR
aggregates [2, 3]. Clinical manifestations of
cardiac involvement may follow later in the
course of disease; however, echocardiography in
patients with only neurologic symptoms may
reveal features of cardiac amyloidosis and
electrocardiography can reveal conduction
defects early in the course of the condition
[75, 76]. In some TTR mutants such as Thr60Ala
(p.Thr80Ala), cardiac involvement may be seen
early or as the first phenotypic manifestation
[77], early and frequent carpal tunnel
syndrome, predominant negative sensory
symptoms at onset, significant vibration
deficits, as well as a non-length-dependent
progression of motor deficit are also
characteristic [78]; while for patients with the
Ser77Tyr mutation, the distinguishable features
are late-onset ([50 years) of disease and
frequent ataxic phenotype [79]. Neurologic
and cardiac deterioration progress relentlessly
during active TTR amyloidogenesis, typically
leading to death within 5–15 years of symptom
onset [66]. It is worth noting that for patients
with the Val30Met mutation and whose disease
onset occurs at an older age ([50 years), studies
of the disease history revealed that the initial
manifestation of amyloidosis was somatic
neuropathy, and the mean duration of the
disease onset to death was 7.3 years [76].
However, for many late-onset cases, due to the
inconspicuous nature of the symptoms (i.e.,
autonomic dysfunctions and sensory
dissociation), they are often misdiagnosed as
other neuropathies [75]. In addition, distinctive
clinical presentation has been found in
late-onset cases with the Val30Met mutation
from non-endemic areas that differs from that
of conventional early-onset cases in endemic
foci [79, 80]. Consequently, late-onset cases are
still under-recognized and an appropriate
diagnosis may benefit from examinations for
subclinical cardiac amyloidosis.
In the exclusive or predominant cardiac
phenotype, known as hereditary TTR amyloid
cardiomyopathy, amyloid is found throughout
the cardiovascular system, including the valves,
ventricles, atria, and the conduction system,
leading to left ventricular wall thickening with a
non-dilated left ventricle and impaired
longitudinal contraction, and resulting in
congestive heart failure and arrhythmias [67,
73, 81]. Survival data for hereditary TTR
amyloid cardiomyopathy are not as well
documented as for TTR-FAP, but the prognosis
is known to be poor with median survival from
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diagnosis ranging from 25.6 to 36.4 months in
three small series [82–84], and with death
primarily from heart failure or sudden death
[85]. The most common mutation associated
with TTR amyloid cardiomyopathy is Val122Ile
(p.Val142Ile), which is found in up to 4% of
African Americans [86, 87]. The level of
penetrance of this mutation has yet to be fully
elucidated [87]; 10% of Afro-Caribbean patients
with acute decompensated heart failure carry
the Val122Ile mutation [88]. Other pathogenic
TTR mutations are less prevalent, and often lead
to a more ‘mixed’ phenotype of neurologic and
multi-organ system involvement [67].
In TTRwt amyloidosis, WT TTR tetramers
dissociate into monomers, misfold, and
undergo amyloidogenesis. Biopsies from
gastrointestinal tract and subcutaneous
tissue of TTRwt amyloidosis patients
confirmed amyloid deposits in 44% (4/9) of
the samples [89]. At autopsy, up to 22–25% of
individuals [80 years of age, and 32% of
adults over the age of 75 with heart failure
and a preserved ejection fraction, have
demonstrable TTR amyloid deposits in
cardiac tissue (mainly found inside the
ventricular wall in a patchy plaque-like
shape) albeit usually mild in extent [85, 89,
90]. The process is not well understood but
seems to be related to ageing and possibly to
destabilizing post-translational modifications.
Cardiac amyloidosis is the primary feature of
those exhibiting active TTRwt amyloidosis,
generally a late-onset sporadic condition
Table 1 Clinical PK parameters of tafamidis [100, 101]
PK parameters Values
AUC0-inﬁnity, mean (SD), ng  h/mL 47,864.31 (11,380.38)
AUClast(female), lgh/mL 60.8
AUClast(male), lgh/mL 51.9
Apparent total clearance, mean (SD), L/h 0.44 (0.12)
Cmax, mean (SD), ng/mL 1430.93 (91.0)
Cmax(female), mean, lg/mL 1.12
Cmax(male), mean, lg/mL 1.23
Cmax(SS), lg/mL 2.7
Cmin(SS), lg/mL 1.6
t1/2(single dose), mean (SD), h 53.86 (16.04)
t1/2(SS), h 59
tmax(fasted), median (range), h 1.75 (0.50, 6.00)
tmax(fed), median (range), h 4 (1.50, 12.00)
Vc/F (95% CI), L 0.482 (0.366, 0.598)
Vp/F (95% CI), L 18.9 (17.6, 20.2)
AUC mean area under the concentration–time curve, CI conﬁdence interval, Cmax maximum plasma concentration, Cmin
minimum plasma concentration, PK pharmacokinetic, SD standard deviation, SS steady state, Tmax time to reach Cmax, Vc/F
volume of distribution of the central compartment, Vp/F volume of distribution of the peripheral compartment
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Table 2 Stabilization of transthyretin tetramer mutants by tafamidis in an ex vivo study [105]
Mutation Measurable vehicle (DMSO) FOI values Stabilization demonstrateda
Cys10Arg Yes Yes
Asp18Glu Nob; Retest: Yes Yesc; Retest: Yes
Pro24Ser Yes Equivocald
Ala25Ser Yes Yes
Val30Gly Nob; Retest: Yes Yesc; Retest: Yes
Arg34Ser Yes Yes
Arg34Thr Yes Yes
Lys35Thr Yes Yes
Ala36Pro Yes Yes
Asp38Ala Yes Yes
Trp41Leu Yes Yes
Gly47Glu Yes Yes
Thr49Ala Yes Yes
Ser50Arg Yes Yes
Glu54Gln Yes Yes
Glu54Lys Yes Yes
Leu55Gln Yes Yes
Thr56Lys Yes Yes
Phe64Ser Nob Yesc
Tyr69His Yes Yes
Val71Ala Yes Yes
Tyr78Phe Nob Yesc
Ile84Ser Yes Yes
His88Arg Yes Yes
Glu89Gln (2 patients) Yes Yes
Ala97Ser Yes Yes
Tyr114Cys Yes Yes
DMSO dimethylsulfoxide, FOI fraction of initial
a Percent stabilization C 32%
b DMSO vehicle FOI was zero, therefore percent stabilization could not be determined
c FOI in tafamidis-spiked sample (but not DMSO-spiked sample) was quantiﬁable, suggesting the sample was indeed
stabilized by tafamidis
d Deemed stabilized but upon retesting, did not cross 32% stabilization threshold (26% stabilization)
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Table 3 Summary of completed clinical trials evaluating tafamidis
Fx-005 [7] Fx-006 [8] Fx1A-201 [106] Fx1B-201 [107]
Study design 18-month, randomized,
placebo-controlled,
double-blind
12-month, open-label
extension of Study Fx-005
12-month, open-label,
non-comparative
12-month, open-label,
non-comparative
Control Placebo None None None
ITT population Tafamidis (T): n = 64
Placebo (P): n = 63
T–T: n = 38
P–T: n = 33
T: n = 21 T: n = 35
TTR genotype Val30Met Val30Met Non-Val30Met, non-Val122Ile
mutant
Val122Ile or wild-type
Main eligibility criteria Documented Val30Met
mutation
Biopsy-conﬁrmed
amyloidosis
Peripheral or autonomic
neuropathy with
Karnofsky
performance status
C50
Completion of the Month
18 visit of Study Fx-005
Biopsy-conﬁrmed amyloidosis
Documented non-Val30Met,
non-Val122Ile TTR mutation
Peripheral and/or autonomic
neuropathy and/or
cardiomyopathy with
Karnofsky performance status
C50
Documented TTR
amyloid
cardiomyopathy
Val122Ile or wild-type
TTR conﬁrmed by
DNA sequencing
NYHA classiﬁcation
I–II
or
Completion of TRACS
Study [120]
Primary endpoint Treatment group
difference in:
NIS-LL response to
treatment, deﬁned as
\2 point increase in
NIS-LL from baseline
to 18 months
Mean change from
baseline to 18 months
in Norfolk TQOL
score
Safety data on chronic use of
tafamidis
TTR stabilization at week 6 TTR stabilization at
Week 6
Location(s) Argentina, Brazil, France,
Germany, Portugal,
Spain, and Sweden
Argentina, Brazil, France,
Germany, Portugal, Spain,
and Sweden
France, Germany, Italy, and USA USA
Baseline characteristics (in ITT population)
Age, years Median (percentile
range)
T: 35.5 (31 to 44)
P: 34.0 (29 to 47)
Median (range)
T–T: 37.5 (26 to 76)
P–T: 36.0 (24 to 73)
Median (percentile range)
64.3 (56.9 to 70.8)
Median (percentile
range)
76.3 (72.1 to 79.3)
NIS-LL score (scale 0 [normal] to 88
points)
T: mean (SD), 8.4
(11.4); median (range),
4.0 (0 to 54)
P: mean (SD), 11.4
(13.5); median (range),
6.0 (0 to 57)
T–T: mean (SD), 8.4 (13.2);
median (range), 5.3 (0 to
65)
P–T: mean (SD), 17.5
(20.8); median (range),
10.0 (0 to 75)
Mean (SD), 27.6 (24.7)
Median (range), 18.0 (0 to 69.9)
N/A
Norfolk QOL-DN (TQOL, scale –2
[best] to 138 points)
T: mean (SD), 27.3
(24.2); median (range),
19.0 (–1 to 110)
P: mean (SD), 30.8
(26.7); median (range),
22.0 (0 to 107)
T–T: mean (SD), 21.1
(21.9); median (range),
11.0 (–1 to 97)
P–T: mean (SD), 38.1
(31.9); median (range),
28.0 (–1 to 96)
Mean (SD), 47.8 (35.1)
Median (range) 38.0 (5.0 to
104.0)
N/A
Outcomes of interest (in ITT population, if not otherwise indicated)
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primarily affecting men [62]. In two separate
observational studies, the prevalence of
sensory neuropathy among patients with
symptomatic TTRwt amyloidosis was around
28% and nearly half had a history of carpal
tunnel syndrome apparently owing to
amyloid deposition in the connective tissue
of the transverse carpal ligament [69, 84].
Table 3 continued
Fx-005 [7] Fx-006 [8] Fx1A-201 [106] Fx1B-201 [107]
Proportion of patients with TTR
tetramer stabilizationa, % (95% CI)
Week 8
T: 98.4% (95.3 to 100%)
P: 6.7% (0.4 to 13.0%)
T vs. P: p\ 0.0001
Month 18
T: 97.9% (93.9 to 100%)
P: 0.0% (0 to 0%)
T vs. P: p\ 0.0001
Week 6
T–T: 94.6% (81 to 99%)
P–T: 96.8% (83 to 99%)
Month 12
T–T: 94.1% (80 to 99%)
P–T: 93.3% (77 to 99%)
Week 6
94.7% (74.0 to 99.9%)
Month 12
100.0% (80.5 to 100.0%)
Week 6
97.1% (85.1 to 99.9%)
Month 12
87.5% (71.0 to 96.5%)
Effect on polyneuropathy
progression
Proportion of patients
with\2-point increase
from baseline at
Month 18, % (95%
CI)
ITT population
T: 45.3% (33.1 to
57.5%)
P: 29.5% (18.1 to 41.0%)
T vs. P: p = 0.068
Pre-speciﬁed EE
population
T: 60.0% (45.7 to
74.3%)
P: 38.1% (23.4 to 52.8%)
T vs. P: p = 0.041
T–T: Proportion of patients
with\2-point increase
from Fx-005 baseline at
Month 12 (30 months),
18/33 (54.5%)
P–T: Proportion of patients
with\2-point increase
from Fx-006 baseline at
Month 12 (12 months),
18/30 (60.0%)
Change from baseline to Month
12
NIS-LL
Mean (SD): 2.7 (6.2)
95% CI: –0.4 to 5.8
Median (range): 1.0 (–10.5 to
11.5)
NIS-UL
Mean (SD): 2.5 (7.4);
95% CI: –1.2 to 6.2
Median (range): 0.5 (–6.0 to
18.0)
N/A
Effect on deterioration in Norfolk
QOL-DN (TQOL)
LS mean change (95%
CI) from baseline at
18 months in TQOL,
points:
ITT population
T: 2.0 (–2.6 to 6.6)
P: 7.2 (2.6 to 11.9)
T vs P: p = 0.116
Pre-speciﬁed EE
population
T: 0.1 (–5.8 to 6.0)
P: 8.9 (2.8 to 15.0)
T vs. P: p = 0.045
Monthly rate of change in
TQOL, points/month
(SEM):
T–T (n = 38):
Fx-005, –0.03 (0.15);
Fx-006, 0.25 (0.20)
P–T (n = 33):
Fx-005, 0.61 (0.16);
Fx-006, –0.16 (0.21)
Change from baseline to Month
12 in TQOL, points
Mean (SD): 0.1 (18.0)
95% CI: –8.9 to 9.0
Median (range): 1.0 (–42.0 to
27.0)
N/A
CI conﬁdence interval, EE population efﬁcacy-evaluable population deﬁned as all randomized patients who received C1 dose of study drug, had C1 post-baseline
assessment for both co-primary endpoints, and completed the study per protocol (tafamidis, n = 45; placebo, n = 42), ITT population intent-to-treat population, LS
mean least square mean, NIS-LL neuropathy impairment score-lower limb, NIS-UL neuropathy impairment score-upper limb, percentile range 25th to 75th
percentile, NYHA New York Heart Association, SD standard deviation, SEM standard error of the mean, TQOL self-reported quality of life score (from the Norfolk
Quality of Life-Diabetic Neuropathy questionnaire), TRACS Transthyretin Amyloidosis Cardiac Study, TTR transthyretin
a Percentage stabilization values (post-treatment relative to pre-treatment) falling above the upper 95% CI of mean percent stabilization in placebo-treated healthy
volunteers were considered to be ‘‘stabilized’’
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RATIONALE FOR DEVELOPMENT
OF TAFAMIDIS
Three separate but reinforcing clinical
observations suggested that molecules
stabilizing the TTR tetramer may be effective
in treating the TTR amyloidoses. First, in 1990,
Holmgren et al. [91] showed that it was possible
to halt the progression of polyneuropathy in
patients with TTR-FAP by orthotopic liver
transplantation using donors carrying two WT
TTR genes, which replaces mutant TTR with a
native allele, affording a more stable and less
amyloidogenic TTR tetramer. Second, a clinical
observation showed that a domino recipient of
a liver graft from a patient with Val30Met
amyloidosis developed amyloidosis [92]. Third,
in the 1990s, it was observed that some
Portuguese individuals with symptomatic
TTR-FAP had uncharacteristically mild
symptoms [93]. Gene sequencing studies
revealed that these individuals are compound
heterozygotes harboring a Val30Met mutation
on allele 1 and a Thr119Met (p.Thr139Met)
mutation on allele 2, conferring protection
against disease development [93].
Incorporation of Thr119Met subunits into
tetramers containing disease-associated
subunits increases the kinetic stability of the
tetramer, slowing tetramer dissociation and
suppressing disease [42, 44, 93, 94].
Binding of either T4 or holo-retinol-binding
protein stabilizes the TTR tetramer, preventing
its dissociation into amyloidogenic monomers
[95, 96]. Notably, approximately half of TTR
circulating in blood lacks a bound ligand. These
observations provided a strong rationale to
develop small molecule ligands that bind to
the largely unoccupied T4 binding pockets and
stabilize the native TTR tetramer as a potential
pharmacotherapy to prevent TTR
amyloidogenesis [13].
Numerous, structurally distinct, small
molecules that bind to the T4 binding sites
were found to inhibit amyloid fibril formation
in vitro, by kinetically stabilizing the
quaternary structure of the TTR tetramer [13,
23, 44]. These TTR kinetic stabilizers included
certain non-steroidal anti-inflammatory drugs
(NSAIDs) such as diflunisal [23, 97, 98].
However, since NSAIDs are associated with
gastrointestinal, renal, and cardiac side effects
[99], attention turned to the benzoxazole
carboxylic acids. Of these, tafamidis (Fig. 1b, c)
was selected for clinical development due to its
lack of NSAID-activity, good oral bioavailability,
and low toxicity profile.
CLINICAL PHARMACOKINETICS
OF TAFAMIDIS
Tafamidis is highly bound to plasma proteins
(binding rate[99.5%) with glucuronidation as
the major metabolic pathway, and the major
circulating form in plasma is parent compound.
In healthy volunteers, tafamidis was rapidly
absorbed after a single oral dose of 20 mg. The
median time (Tmax) to reach the maximum
concentration (Cmax) was approximately 2.0 h.
Administration of tafamidis with food reduces
the rate of absorption, but overall extent of
absorption is not affected. Pharmacokinetic
(PK) parameters were similar after single and
repeated dosing, indicating a lack of metabolic
induction or inhibition by tafamidis.
Elimination of tafamidis is slow, with a mean
half-life of approximately 59 h. Steady state (SS)
was achieved by day 14 after once-daily dosing
with 20 mg tafamidis for 14 days, with Cmax(ss)
and Cmin(ss) at 2.7 and 1.6 lg/mL, respectively
(Table 1) [100, 101].
Based on population PK analysis, SS
clearance of tafamidis was similar in subjects
with creatinine clearance\80 and[80 mL/min.
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However, compared with healthy volunteers,
patients with moderate hepatic impairment
(Child–Pugh Score of 7–9 inclusive) had
decreased systemic exposure (by approximately
40%) of tafamidis. In subjects [60 years old,
clearance following repeated tafamidis 20 mg
once daily was 19% slower and the Cmax(ss) was
21% higher compared with those\60 years old
[100].
TTR STABILIZATION BY TAFAMIDIS
Nonclinical in vitro and ex vivo experiments
have demonstrated that tafamidis binds with
selectivity, high affinity, and negative
cooperativity (KD1 * 2 nM, KD2 * 200 nM) to
recombinant WT TTR and to TTR in human
plasma [5, 102]. Tafamidis exhibits comparable
potency against dissociation of WT TTR and
heterotetramers of[35 TTR mutants, including
the two most common amyloidogenic mutants,
Val30Met and Val122Ile [5].
As stated in previous publications [5, 102],
an indirect means of detecting TTR monomer
formation under physiologic conditions is to
employ subunit exchange experiments [42, 103,
104], in which, two homotetramers composed
of WT TTR subunits with and without the
N-terminal negatively charged FLAG-tag were
mixed, and time-dependent subunit exchange
was then quantified using ion-exchange
chromatography at physiologic pH. Since TTR
tetramer dissociation should be slowed by
tafamidis, the subunit exchange between the
untagged WT TTR homotetramer and the
FLAG-tagged WT TTR homotetramer would be
slowed in the presence of tafamidis.
Experiments showed that subunit exchange
was complete in the vehicle control after 96 h
of incubation at 25C when the pH was 7.0;
while in the presence of tafamidis, the fraction
of subunit exchange was considerably lower.
For instance, at a tafamidis:TTR tetramer molar
ratio of 1, the subunit exchange was 15% after
24 h compared with 70% in the absence of
tafamidis; and when the molar ratio was 1.50,
the fraction of exchange was\10% after 11 days
[5]. Based on these findings, it has been
concluded that tafamidis decreases the rate of
tetramer dissociation at physiologic pH in a
dose-dependent manner.
By measuring TTR tetramers in plasma, an
immunoturbidimetric assay [98] (for details see
the supplementary material) was used in
nonclinical and clinical studies to measure a
key pharmacodynamic endpoint as it
demonstrated that tafamidis stabilized TTR
mutants ex vivo [5]. In this assay, 4.8 lM urea
was added to plasma samples for over 48 h,
which was followed by glutaraldehyde
crosslinking, and then the remaining
tetrameric TTR was quantified using a TTR
antibody [5, 98, 102]. In the absence of
tafamidis and the presence of urea, TTR
tetramers dissociate and irreversibly unfold
into monomers, which are extensively
modified by glutaraldehyde and thus are not
detected by TTR antibody precipitation. In the
presence of tafamidis, plasma samples are
resistant to TTR tetramer dissociation induced
by urea and epitope modification by
glutaraldehyde. The immunoturbidity signals
are preserved since the TTR tetramer structure is
preserved. Therefore, the percentage of TTR
stabilization can be calculated as:
Percent TTR stabilization
¼ FOI dosed FOI baseline
FOI baseline
 100;
where FOI (fraction of initial) is the percentage
decrease in TTR immunoturbidity of the plasma
samples after 48-h incubation with urea, FOI
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baseline shows tetramer dissociation at baseline
while FOI dosed shows tetramer dissociation
after tafamidis dosing. After assessment of
random variation in TTR stabilization in
placebo-treated healthy volunteers, a cut-off
value of 32% was chosen, above which TTR
tetramers are considered to have been stabilized
by tafamidis. Nonclinical studies suggested that
Fig. 1 TTR amyloidogenesis and TTR stabilization by
tafamidis (a). The TTR amyloidogenic cascade. TTR is a
tetrameric protein that can be destabilized by mutations in
TTR, resulting in its dissociation into monomers that
rapidly misfold and misassemble into aggregates, including
pathologic structures associated with TTR amyloidosis [23,
40–45]. Also shown are the molecular structure of
tafamidis (b) and the co-crystal structure of tafamidis
(black, ball-and-stick) bound to a TTR tetramer (ribbon)
(c). TTR transthyretin
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a 1–1.5:1 tafamidis:TTR stoichiometry should
be sufficient to stabilize TTR and inhibit
tetramer dissociation in human plasma (Pfizer,
data on file). In two clinical studies of healthy
volunteers with orally administered tafamidis,
mean percent TTR stabilization increased with
increasing plasma tafamidis:TTR stoichiometry
and appeared to reach a plateau (Fig. 2), but at
ratios higher than projected from nonclinical
data.
TTR TETRAMER STABILIZATION
IN PLASMA OF TTR AMYLOIDOSIS
PATIENTS
An ex vivo study on plasma samples from 28
patients with TTR amyloidosis showed that
tafamidis can increase the stability of the
native tetrameric structure of multiple
amyloidogenic TTR variants. Eligible subjects
had been diagnosed with TTR amyloidosis and
had a documented non-Val30Met,
non-Val122Ile TTR mutation, and study
protocol and informed consent
documentation were approved by the relevant
institutional review boards. The stability of
tetrameric TTR in the plasma samples [TTR
baseline concentration range 4.2–29.6 mg/dL
(0.76–5.38 lM)] was compared in the presence
or absence of 7.2 lM tafamidis, using the
immunoturbidimetric assay. Tafamidis
increased the stability of the TTR tetramer in
26 of 27 TTR mutants (Table 2) [105]. One
mutant (Pro24Ser) demonstrated equivocal
results in vitro. TTR stabilization was also
found in patients with TTRwt amyloidosis who
were treated with tafamidis (20 mg orally, once
daily). Compared with the untreated TTRwt
amyloidosis patients and untreated
age-matched controls, those treated with
tafamidis showed a [73% decrease in the
tetramer dissociation rate, and the rate of
Fig. 2 Percent change from baseline in TTR tetramer fold
stabilization relative to tafamidis:TTR molar ratio in the
plasma of healthy volunteers. The data presented originate
from two Phase 1, randomized, double-blind, ascending
dose tolerance studies. In study Fx-002, healthy adults aged
18–65 years with a body mass index of 19–29 kg/m2
administered single doses of up to 120 mg tafamidis. In
study B3461040 (ClinicalTrials.gov identiﬁer,
NCT01655511), healthy adults aged 21–55 years with a
body mass index of 17.5–30.5 kg/m2 administered single
doses of up to 480 mg tafamidis. TTR transthyretin
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tetramer dissociation (as measured by subunit
exchange) correlated strongly with tafamidis
concentration in the plasma (R2 = 0.929) [102].
Evidence showed that tafamidis binds and
stabilizes the functional TTR protein (i.e., the
tetrameric form) and the stabilized tetramers are
less likely to dissociate into monomers;
however, the relationship between increased
TTR stabilization and the increase in
concentration of circulating functional TTR
requires further investigation [7, 8, 102].
THERAPEUTIC USE
Transthyretin stabilization, efficacy, and safety
of treatment with oral tafamidis 20 mg once
daily have to date been evaluated in four
completed clinical trials in polyneuropathy
and cardiomyopathy (Table 3) [7, 8, 106, 107]:
1. The pivotal Fx-005 study, a randomized,
placebo-controlled, 18-month trial in 128
patients with early-stage Val30Met-FAP,
showed that tafamidis successfully
increased TTR tetramer stability in 98% of
the tafamidis group throughout the
18-month treatment period and this
increase in TTR stability was associated
with a reduction in neurologic
deterioration, preservation of nerve
function (large and small fibers), improved
nutritional status, and maintained quality
of life after 18 months compared with
placebo group (Fig. 3) [7].
2. In Study Fx-006, a 12-month, open-label
extension study to Study Fx-005, where 86
of the 91 patients who had completed the
Month 18 visit of Fx-005 either continued
to receive tafamidis (tafamidis–tafamidis) or
were switched to tafamidis
(placebo–tafamidis) for 12 months,
tafamidis conferred increased TTR tetramer
stability in[93% of participants. Moreover,
the observed slowing of disease progression
among the tafamidis-treated patients of
Fx-005 was extended to 30 months in the
tafamidis–tafamidis cohort and the rate of
disease progression was reduced in the
placebo–tafamidis group over the
12-month active treatment period (Fig. 4)
[8].
Fig. 3 Least square mean (±standard error) change from
baseline to Month 18 in efﬁcacy measures (Fx-005, ITT
population) [7]. Least square mean estimates and p values
are based on a repeated measures analysis of variance model
using observed values with change from baseline as the
dependent variable. R7 NTs nds summated 7 nerve tests
normal deviates, R3 NTSF nds summated 3 nerve tests
small-ﬁber normal deviates, ITT intention to treat, mBMI
modiﬁed body mass index,NIS-LL neuropathy impairment
score—lower limb, TQOL total quality of life
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3. Fx1A-201, a Phase 2, open-label study in 21
patients with TTR-FAP due to eight different
non-Val30Met TTR mutations,
demonstrated general tolerability and
efficacy of tafamidis on TTR tetramer
stability in [94% of the polyneuropathy
patients with other TTR genotypes. These
patients were older, had longer disease
duration, and more severe disease—
frequently including cardiac
abnormalities—at baseline than the Fx-005
population [106].
4. Fx1B-201, a Phase 2, open-label, 12-month
study (ClinicalTrials.gov identifier,
NCT00694161), found that tafamidis was
associated with an acceptable safety profile
and successfully increased the kinetic
stability of TTR tetramers in the vast
majority (96.8%) of 35 patients with
Val122Ile or TTRwt amyloidosis [107].
Fig. 4 Mean (±standard error) change from baseline to on-treatment visits in efﬁcacy endpoints measured in the ITT
populations of Studies Fx-005/Fx-006 and Fx1A-201 [7, 8, 106]. ITT intention to treat
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Patients in these trials had variable
characteristics and severity of symptoms at
baseline. Therefore, the differences observed in
clinical efficacy and safety across these trials
may be confounded by the patients’ underlying
disease and comorbid conditions.
SAFETY
Adverse Events
The risk of adverse events (AEs) is difficult to
evaluate based on the small number of patients
who received tafamidis to date. The available
clinical trial data indicate that tafamidis was
generally well tolerated, with the type and
frequency of the most commonly reported AEs
partly dependent on the primary phenotype
and clinical status of the patient in addition to
any drug effects. Many of the AEs with an
overall incidence[5% are of a similar nature as
the symptoms of the underlying disease.
In the Fx-005 study of patients with
early-stage Val30Met-FAP, the overall
incidences of any AE, AE leading to drug
discontinuation, and serious AEs were similar
in the tafamidis and placebo treatment groups
[7]. Furthermore, the overall incidence rates of
AEs among the polyneuropathy patients in
studies Fx-005, Fx-006, and Fx1A-201 were
similar [7, 8, 106]. Differences in incidence
rates of individual AEs across these studies were
generally not clinically meaningful. One
exception was treatment-emergent urinary
tract infection (UTI): 15 of 65 tafamidis-treated
patients (23%) in Fx-005 reported a UTI
compared with 8 of 63 placebo-treated
patients (13%) [7]. UTIs were also reported by
12 of 85 tafamidis-treated patients (14%) in
Fx-006 [8], and by 3 of 35 patients (9%) in
Fx1B-201 [107]. In contrast, none of the 21
patients who received tafamidis in the
open-label Fx1A-201 study developed a UTI
[106]. Additionally, a higher incidence of
diarrhea was reported in the tafamidis group
than in the placebo group in the pivotal Fx-005
study (17 of 65 [26.2%] vs. 11 of 63 [17.5%]) [7].
Diarrhea events were also reported by 7 of 85
patients (8.2%) in Fx-006 [8], by 5 of 21 patients
(23.8%) in Fx1A-201 [106], and by 7 of 35
patients (20.0%) in Fx1B-201 [107]. Also of note
was the incidence of patients experiencing a fall
in Fx-005 (0 of 65 tafamidis-treated patients vs.
1 of 63 placebo-treated patients), Fx-006 (2 of 85
patients), Fx1A-201 (5 of 21 patients), and
Fx1B-201 (3 of 35 patients).
In the Fx1B-201 study of TTR amyloid
cardiomyopathy, 15 of 35 patients had a
serious AE, the most common being cardiac
disorders (12 patients) including heart failure
(9 patients) and atrial fibrillation (3 patients)
[107]. Four patients reported six SAEs that were
considered possibly related to tafamidis,
namely, syncope, ataxia, falls (reported by two
patients), hemorrhagic stroke, and cardiac heart
failure [107].
Deaths
In the Fx-005 study, five Val30Met-FAP patients
(two receiving tafamidis, three receiving
placebo) died, all after liver transplant [7].
These deaths were considered unrelated to the
study drug. No deaths were reported in Fx-006
or Fx1A-201 [8, 106].
Two TTRwt amyloidosis patients died during
the Fx1B-201 study (causes of death were
hemorrhagic stroke and amyloid light-chain
[AL] amyloidosis) [107]. These deaths were
considered unrelated to the study drug. The
patient with AL amyloidosis had been enrolled
in the study based on positive amyloid biopsy,
absence of evidence of a plasma cell dyscrasia,
and positive TTR staining by immunogold
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electron microscopy. After an unexplained,
rapid decline at 11 months, a re-biopsy
demonstrated amyloid positive for
immunoglobulin light chain and no evidence
of TTR deposition, after which the patient
withdrew from the study, and died from
complications due to pleurodesis treatment for
AL amyloidosis. Subsequent re-evaluation of the
biopsies using mass spectrometry demonstrated
that both had amyloid deposits derived from
light chains, without evidence of TTR.
DISCUSSION
The nonclinical and clinical studies described
here demonstrate that tafamidis kinetically
stabilizes TTR tetramers thereby slowing TTR
tetramer dissociation. TTR tetramer disassembly
is the rate-limiting step of amyloidogenesis and
its inhibition is expected to inhibit the
amyloidogenesis cascade and, in turn, to slow
disease progression. Strong evidence for this
concept was that tafamidis treatment slowed
neurologic disease progression in patients with
Val30Met amyloidosis compared with placebo
[7], and by the fact that modest deterioration in
neurologic function was observed in patients
with TTR-FAP caused by non-Val30Met
mutations and who were treated with
tafamidis [106].
Tafamidis increases the kinetic stability of a
large number of TTR variants, as well as for
TTRwt, suggesting that the tetramer
stabilization effect may extend to many of the
[100 TTR genotypes associated with
amyloidosis. Furthermore, tafamidis proved
effective in stabilizing TTR throughout the
treatment period in a number of study
populations, differing in severity of disease,
phenotype(s), and TTR genotype. While TTR
tetramer stabilization along with patient- and
disease-related factors may predict clinical
response, placebo data in Val30Met-FAP
patients suggest that lack of TTR tetramer
stabilization predicts clinical nonresponse.
In patients with early-stage Val30Met
amyloidosis who were treated with tafamidis, the
rate of neurologic deterioration was slowed,
quality of life was maintained, and nutritional
status was improved, compared with
placebo-treated patients [7, 108]; and TTR
stabilization was associated with slower disease
progression [8]. There was also some indication
that 12 months of open-label tafamidis might
improve some signs and symptoms of TTR-FAP
associated with non-Val30Met mutations in older
patients with more advanced disease [106].
Considering the mechanism of action and the
available results on TTR stabilization, the tafamidis
effect on disease progression is expected to extend
to TTR amyloid polyneuropathy due to
non-Val30Met mutations [106].
Long-term study demonstrated that the
clinical benefits experienced by Val30Met-FAP
patients receiving tafamidis were sustained for
the duration of the study (30 months for Study
Fx-006) [8]. Furthermore, there was an
advantage of initiating treatment earlier, or at
an earlier stage of disease, although those
starting treatment later still experienced
patterns of slowed disease progression [8],
suggesting that earlier initiation of tafamidis
therapy may result in improved clinical
outcomes. These results underscore the need
to identify subjects early and treat
Val30Met-FAP soon after the diagnosis is
made. Moreover, the summary of product
characteristics in Europe states: ‘‘Treatment
should be initiated by and remain under the
supervision of a physician knowledgeable in the
management of patients with transthyretin
amyloid polyneuropathy’’ [100].
Noticeably, across the different groups of
tafamidis-treated patients with TTR
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amyloidosis, including those with
cardiomyopathy and a small number of
patients with renal impairment, the AEs (e.g.,
UTI, respiratory infections, diarrhea, headache,
pain, and vomiting) were generally mild to
moderate in severity, with no major safety
concerns identified [7, 8, 106, 107]. Overall,
tafamidis 20 mg once daily is safe and well
tolerated.
In cardiomyopathy patients receiving
open-label tafamidis, measures of disease
progression did not deteriorate markedly
during 12 months [107] warranting further
evaluation of tafamidis in TTR amyloid
cardiomyopathy. In addition, it has been
reported that increasing the dose of tafamidis
appears to be safe [109, 110]. Currently, a
multicenter, double-blind, placebo-controlled,
randomized, Phase 3 study is being conducted
(ClinicalTrials.gov identifier, NCT01994889) to
investigate the efficacy, safety, and tolerability
of tafamidis 20 or 80 mg once daily for patients
with TTR cardiomyopathy.
While tafamidis treatment may present
benefits to patients with polyneuropathy or
cardiomyopathy, it is unlikely that CNS
manifestations of TTR amyloidosis, such as
leptomeningeal or ocular amyloidosis, would
be effectively treated with oral tafamidis
therapy, as the drug does not penetrate
extensively into the brain or eye in rats.
Rather, tafamidis accumulates preferentially in
the bloodstream and in the liver, which is the
primary source of mutant TTR.
Tafamidis is the only currently approved
pharmacotherapy for the treatment of
early-stage TTR-FAP, with ongoing clinical
investigation for TTR-FAC. The favorable
tolerability profile and suitability for long-term
use, further underscore its benefits in patients
with TTR amyloidosis. Diagnosing patients as
early as possible for the initiation of tafamidis
therapy before substantial accumulation of
amyloid in the nerves and organs is of
paramount importance.
Following regulatory approvals in the
European Union and several countries in Latin
America and the Asia-Pacific, tafamidis has
emerged as a new standard of care for patients
with TTR-FAP. Prior to tafamidis, the only
disease-modifying treatment available for TTR
amyloidosis was liver transplantation
[111–117]. However, liver transplantation is an
invasive procedure requiring lifelong
immunosuppressive therapy and has limited
applicability to a carefully selected cohort of
primarily Val30Met patients (non-elderly) with
early-stage disease, and good nutritional status
[111, 117–119].
SUMMARY
Tafamidis is a well-tolerated and efficacious
pharmacotherapy for the treatment of
early-stage TTR-FAP. It effectively stabilizes
TTR across a number of amyloidogenic TTR
genotypes, including WT TTR, and slows disease
progression. In patients with early-stage
Val30Met amyloid polyneuropathy, tafamidis
delayed neurological deterioration, preserved
nutritional status and quality of life. A Phase
3, randomized, placebo-controlled trial
(ClinicalTrials.gov identifier, NCT01994889) is
currently underway to investigate the efficacy,
safety, and tolerability of tafamidis in patients
with TTR amyloid cardiomyopathy. The
long-term efficacy and safety of tafamidis for
periods up to 5–8 years appears favorable, based
on extension studies from the tafamidis clinical
trial program and real-world experience in
hundreds of patients to date.
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